Current Edition

Five Barriers to Process Automation in PV & How to Overcome Them

At the high-impact R&D end of life sciences, investment in technology is consciously linked to commercial priorities including innovation, efficiency and speed to market. Noting the contrast between potential and progress in clinical trials vs post-marketing/ real-world monitoring, Peter Kohut at Arriello explores the main hurdles preventing greater automation of PV data capture processes within life sciences firms.